Aliqopa (copanlisib) vs Columvi (glofitamab-gxbm)
Aliqopa (copanlisib) vs Columvi (glofitamab-gxbm)
Aliqopa (copanlisib) is a kinase inhibitor used for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. In contrast, Glofitamab (Columvi) is a bispecific monoclonal antibody designed for the treatment of various forms of B-cell non-Hodgkin lymphoma, including those who have relapsed or are refractory after previous therapies. When deciding between these two medications, it is important to consider factors such as the specific type and stage of lymphoma, previous treatments, the patient's overall health, and potential side effects, as the efficacy and safety profiles of these drugs differ and should be discussed with a healthcare provider.
Difference between Aliqopa and Columvi
| Metric | Aliqopa (copanlisib) | Columvi (glofitamab-gxbm) |
|---|---|---|
| Generic name | copanlisib | glofitamab-gxbm |
| Indications | Relapsed follicular lymphoma | Relapsed or refractory B-cell non-Hodgkin lymphoma |
| Mechanism of action | PI3K inhibitor | Bi-specific monoclonal antibody targeting CD20 and CD3 |
| Brand names | Aliqopa | Columvi |
| Administrative route | Intravenous infusion | Intravenous infusion |
| Side effects | Hyperglycemia, hypertension, neutropenia, etc. | Cytokine release syndrome, infusion-related reactions, etc. |
| Contraindications | History of severe allergic reactions to copanlisib | None specifically listed; use caution in patients with active infections or inflammatory disorders |
| Drug class | Antineoplastic agent | Antineoplastic agent |
| Manufacturer | Bayer | Genentech |
Efficacy
Aliqopa (Copanlisib) Efficacy in Treating Lymphoma
Aliqopa (copanlisib) is a kinase inhibitor specifically designed for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. As a phosphatidylinositol-3-kinase (PI3K) inhibitor, Aliqopa disrupts cancer cell growth and survival. In a pivotal phase II clinical trial known as CHRONOS-1, Aliqopa demonstrated significant efficacy in patients with relapsed follicular lymphoma. The overall response rate (ORR) was reported to be 59%, with a complete response rate of 14% and a partial response rate of 45%. The median duration of response was also notable, indicating that Aliqopa can provide a meaningful clinical benefit in this patient population.
It is important to note that the efficacy of Aliqopa was observed in a heavily pre-treated group of patients, which underscores its potential role in the management of relapsed follicular lymphoma. The drug's approval by regulatory agencies such as the FDA was based on the results of this trial, offering an additional treatment option for patients who have limited responses to previous therapies.
Glofitamab (Columvi) Efficacy in Treating Lymphoma
Glofitamab (Columvi) is a novel bispecific monoclonal antibody that targets both CD20 on B-cells and CD3 on T-cells, thereby facilitating the immune system's attack on lymphoma cells. While it is still under investigation and not yet approved for commercial use, early clinical trial results have shown promise in the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. In a phase I study, glofitamab demonstrated an ability to induce complete responses in a proportion of patients with relapsed or refractory B-cell lymphomas.
Although the full efficacy profile of glofitamab is still being determined through ongoing clinical trials, the initial data suggests that it has the potential to be an effective treatment for patients with various forms of lymphoma, particularly those who have exhausted other treatment options. As a part of combination therapies or as a single agent, glofitamab's unique mechanism of action may offer a new avenue for lymphoma treatment pending further investigation and regulatory approval.
Regulatory Agency Approvals
Aliqopa
-
Food and Drug Administration (FDA), USA
Columvi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Aliqopa or Columvi today
If Aliqopa or Columvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us